Tokyo hospital to test viral therapy for tumors

August 16, 2009 The Yomiuri Shimbun

Tokyo University Hospital will begin a clinical test in late August of a viral therapy in which viruses are injected directly into brain tumor patients, according to hospital officials.

It will be the first clinical trial in Japan to use viruses whose has been altered to destroy cancer cells in localized areas.

A team including professor Tomoki Todo of the university's neurosurgery department is focusing on the herpes virus, which is believed to infect cancer cells easily.

As the could damage even healthy cells, the team has altered three genes in the virus so it will reproduce only in cancer cells.

The clinical trial will be conducted on patients who have had a relapse of glioblastoma, the most malignant of .

The virus will be administered to the twice over a two-week period, and the team will monitor such elements as tumor size and whether nerve paralysis occurs.

The hospital is recruiting patients for the trial and is expected to conduct it on a maximum of 21 people, according to the hospital officials.

During an earlier experiment in which glioblastoma were implanted under the skin of mice, the tumors became smaller when the mice were injected with viruses.

However, if no further treatment was given, the tumors swelled to about 30 times their original size within 25 days. There were no abnormalities detected when viruses were injected into healthy mice.

Clinical trials involving the alteration of one or two in viral therapy are currently being conducted in Britain and other countries.
___

(c) 2009, The Yomiuri Shimbun.
Visit the Daily Yomiuri Online at www.yomiuri.co.jp/index-e.htm/
Distributed by McClatchy-Tribune Information Services.

Related Stories

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.